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Abstract: 
Importance: Norepinephrine is currently recommended as the first line 
vasopressor in septic shock; however, early vasopressin use has been proposed 
as an alternative. 
Objective: To compare the effect of early vasopressin vs norepinephrine on 
kidney  failure in patients with septic shock. 
Design, Setting and Participants: A factorial (2x2), double-blind, randomized 
clinical trial conducted in 18 general adult intensive care units in the United 
Kingdom between February 2013 and May 2015, enrolling adult patients who 
had septic shock requiring vasopressors despite fluid resuscitation within a 
maximum of 6 hours after the onset of shock. 
Interventions: Patients were randomly allocated to vasopressin (titrated up to 
0.06 units/minute)  and hydrocortisone (n=101), vasopressin and placebo 
(n=104), norepinephrine and hydrocortisone (n=101), or norepinephrine and 
placebo (n=103). 
Main outcomes and measures: The primary outcome was kidney  failure free 
days during the 28-day period after randomization, summarized as (1) the 
proportion of patients who never developed kidney  failure and (2) median 
number of days alive and free of kidney failure for patients who did not survive, 
who experienced kidney failure, or both. Rates of renal replacement therapy, 
mortality and serious adverse events were secondary outcomes. 
Results:  A total of 409 patients (median age 66 years, 58.2% men ) were 
included in the study with a median time to study drug administration of 3.5 
hours after diagnosis of shock.  The number of survivors who never developed 
kidney failure was 94/165 (57.0%) in the vasopressin group and 93/157 
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(59.2%) in the norepinephrine group (difference -2.3% [95%CI -13.0, 8.5]). The 
median number of kidney failure free days for patients who did not survive, who 
experienced kidney failure, or both was 9 days (interquartile range, 1–24) in the 
vasopressin group and 13 days (interquartile range, 1–25) in the norepinephrine 
group (difference -4 days [95%CI -11, 5]). There was less use of renal 
replacement therapy in the vasopressin group 25.4% vs 35.3% in the 
norepinephrine group (difference -9.9% [95%CI -19.3, -0.6]). There was no 
evidence of a difference in mortality rates between groups. In total 22/205 
(10.7%) patients had a serious adverse event in the vasopressin group vs 17/204 
(8.3%) in the norepinephrine group (difference 2.5% [95%CI -3.3, 8.2]). 
Conclusions and Relevance:  Among adults with septic shock, the early use of 
vasopressin compared with norepinephrine did not improve the number of 
kidney failure free days.  Although these findings do not support the use of 
vasopressin to replace norepinephrine as initial treatment in this situation, the 
confidence interval included a potential clinically important benefit for 
vasopressin, and larger trials may be warranted to assess this further. 
Trial registration number: ISRCTN 20769191 
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Introduction: 
 
In 2015, it was estimated that there are more than 230,000 cases of septic shock 
with more than 40,000 deaths in the US each year.1 In addition to  treating the 
underlying infection, the mainstay of cardiovascular resuscitation in septic shock 
is intravenous fluids and vasopressor treatment. Norepinephrine is the 
recommended first line vasopressor2 but  since a relative vasopressin deficiency 
in septic shock was described there has been growing interest in the use of 
vasopressin as an adjunctive agent.3 Preclinical and small clinical studies have 
suggested that vasopressin may be better able to maintain glomerular filtration 
rate and improve creatinine clearance compared with norepinephrine.4-6 
 The largest trial of vasopressin to date, the Vasopressin and Septic Shock 
Trial (VASST),7 found no difference in mortality overall when vasopressin (up to 
0.03 U/minute) was added to existing norepinephrine treatment compared with 
norepinephrine alone but there was a significantly lower mortality in the 
vasopressin treated patients who had less severe shock (defined as a dose of 
norepinephrine <15µg/min). Additional analyses from VASST and other 
investigations have suggested that early vasopressin might prevent deterioration 
in organ function,5,8 particularly kidney function and that higher doses of 
vasopressin (up to 0.06 U/minute) may be more effective.9 In addition it has 
been proposed that there may be an interaction between vasopressin and 
corticosteroids when used to treat septic shock and that the combination of 
vasopressin and corticosteroids may improve survival10 and reduce the duration 
of shock.11 
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 The Vasopressin vs Norepinephrine as Initial therapy in Septic Shock 
(VANISH) trial was designed to test whether early vasopressin use, titrated up to 
0.06 U/min, would improve kidney outcomes compared with norepinephrine. 
 
Methods: 
Trial design and participants 
The VANISH trial was a factorial (2x2), multi-center, double-blind, 
randomized clinical trial. It was conducted in 18 general adult intensive care 
units (ICU) in the United Kingdom between February 2013 and May 2015. The 
trial protocol is available in supplement 1 and the statistical analysis plan in 
supplement 2. 
Oxford A research ethics committee approved the trial (12/SC/0014). In 
view of the emergency nature of the trial a waiver of initial consent was granted. 
Patients could be enrolled into the trial without prospective consent and then 
written consent was obtained from the patient, or a personal or professional 
legal representative as soon as practically possible. In cases where a legal 
representative gave consent, retrospective written consent was sought once the 
patient regained decision-making capacity. 
Adult patients (≥16 years) who had sepsis (2/4 systemic inflammatory 
response criteria due to known or suspected infection12) and who required 
vasopressors despite adequate intravenous fluid resuscitation, as assessed by 
clinical examination, central venous pressure / oxygen saturation, or other 
physiological parameters using repeated fluid challenges, were eligible for the 
trial. Exclusion criteria were patients who had received a previous continuous 
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infusion of vasopressors during this ICU admission, an ongoing requirement for 
systemic steroid treatment (i.e. known adrenal insufficiency or regular systemic 
steroid therapy within the last three months), end-stage kidney failure, known 
mesenteric ischemia, Raynaud’s phenomenon, systemic sclerosis or other 
vasospastic disease, if the medical team were not committed to full active 
treatment, known pregnancy, enrollment in another interventional trial that 
might interact with the study drugs, or hypersensitivity to any of the study 
drugs.  
 Ethnicity was classified based on medical records, as most patients 
lacked capacity to provide this information at the time of their study enrollment.  
Documentation of ethnicity in patients’ medical records is standard practice 
within UK National Health Service.  The main categories of ethnicity were White, 
Black,  Asian and Other.  Since the vast majority of study participants were white, 
the descriptive statistics utilized a simplified dichotomization of White versus 
Other.    
Randomization and masking: 
Enrollment, randomization and data collection were via an online system 
(InFormTM, Oracle Corp, California, USA). Patients were assigned to one of four 
treatment groups (vasopressin and hydrocortisone, vasopressin and placebo, 
norepinephrine and hydrocortisone, or norepinephrine and placebo) on a 
1:1:1:1 basis with variable block size randomization (four and eight) using 
computer-generated random numbers, stratified by center. The allocation 
sequence was prepared by an independent statistician in the Imperial Clinical 
Trials Unit and concealed from all investigators and treating clinicians. 
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Ampoules of vasopressin (Ferring Pharmaceuticals, Canada), norepinephrine 
(Aguettant Ltd, UK) and hydrocortisone phosphate (Amdipharm Ltd, UK) were 
masked by over-labeling on the body and neck of normal drug ampoules. 
Matching placebo ampoules (0.9% saline) were manufactured by Sharp Clinical 
Services (Powys, UK) who carried out all labeling and treatment pack 
preparation. 
Clinical Management: 
Patients were allocated to receive either vasopressin (titrated up to 0.06 
units / minute) or norepinephrine (titrated up to 12µg / minute) as the initial 
vasopressor infusion (study drug 1) via a central venous catheter, and titrated to 
maintain the target mean arterial pressure (MAP). The protocol recommended a 
MAP of 65-75mmHg but this could be altered by the treating physician if 
clinically indicated.  
Once the maximum infusion rate of study drug 1 was reached patients 
received study drug 2, either 50mg hydrocortisone phosphate or placebo, 
administered as an intravenous bolus 6-hourly for 5 days, 12-hourly for 3 days 
and then once daily for 3 days, as previously reported.13 The drug  could be 
weaned more quickly if the shock had already resolved.  
If the patient was still hypotensive after the first dose of study drug 2 then 
additional open-label catecholamine vasopressors could be administered. As the 
patient recovered, open-label catecholamine vasopressors were reduced first 
and only once the patient was  weaned off open label vasopressors was study 
drug 1 then reduced. Once study drug 1 was weaned off, if there was recurrent 
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hypotension within 24 hours the study drug was restarted; if hypotension 
recurred after 24 hours open-label vasopressors were used at local physician 
discretion. All other treatment was at physician discretion, based on the 
Surviving Sepsis Campaign guidelines at that time.14 
Patients could present and be recruited from any part of the hospital 
prior to ICU admission. Although the aim was to use study drug 1 as the initial 
vasopressor, study drugs could not be stored in multiple locations within the 
hospitals. Therefore, in an emergency when immediate treatment was required 
patients could be initially resuscitated using usual (open-label) clinically 
prescribed vasopressors. In this situation the patient had to be enrolled into the 
trial within six hours of commencing the open-label vasopressor infusion. As the 
study drug infusion was titrated up, as detailed above, the initial open-label 
vasopressor infusion was weaned off as quickly as possible in order to maximize 
the study drug infusion rate.  
Outcome measures: 
 The primary outcome of the trial was kidney failure free days, i.e. the 
number of days alive and free of kidney failure, defined by the Acute Kidney 
Injury Network (AKIN) group stage 3 definition15, during the 28 days after 
randomization, with no additional penalty for death. This outcome measure was  
not normally distributed and had a large spike in frequency at 28 days, the point 
at which the measure was  truncated, representing survivors who never 
developed kidney failure. Therefore the prospective plan was to report the data 
using two summary measures 1) the proportion of survivors who never 
developed kidney failure (the spike at 28 days) and 2) the median number of 
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days alive and free of kidney failure for the other patients who did not survive, 
who experienced kidney failure, or both at any time.  
 Secondary outcomes included rates and duration of renal replacement 
therapy, length of kidney failure in survivors and non-survivors, 28-day, ICU and 
hospital mortality rates, organ failure free days in the first 28 days, assessed 
using the sequential organ failure assessment (SOFA) score.16 
 
Statistical Analysis: 
 A sample size of 400 was chosen to provide 80% power to detect a 20-
25% relative reduction of risk of developing kidney failure if treated with 
vasopressin compared to norepinephrine, assuming an overall incidence of acute 
kidney failure of 30% to 50%8,11 and a significance level of 0.05. The calculations 
were based on simulation, assuming a Mann-Whitney U test for analysis. To 
allow for a 3% withdrawal of consent, in line with previous critical care studies 
within the UK17, 412 patients was the recruitment target.  
 The primary analysis tested for a difference between the distribution of 
kidney failure free days for all patients randomized to vasopressin compared to 
those randomized to norepinephrine using a Mann-Whitney U test. The main 
analysis was a modified intention-to-treat basis (patients who did not receive 
study drug as they had died or recovered or were found to be ineligible after 
randomization were excluded).  However, because  not all patients would 
require study drug 2, analysis was also carried out on an “as treated” basis, with 
patients not requiring study drug 2 allocated to the placebo group, and re-
allocation of any cross-overs. A further “per protocol” analysis was carried out in 
 11 
which any patients not receiving the allocated study drugs or cross-overs were 
excluded. Logistic regression models and Cox regression models were used to 
compare renal replacement therapy and mortality between the four treatment 
groups and test for a potential vasopressin / hydrocortisone interaction, on an 
intention to treat basis, accounting for study site using a hierarchical model for 
the logistic regression and stratification for the Cox model. All analyses were 
carried out using R version 3.1.3.18, and a p-value < 0.05 was considered 
statistically significant using 2-sided tests. 
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Results: 
 Figure 1 shows the patient flow in the trial. The most frequent reason for 
screening failure was exceeding the six-hour recruitment window. A total of 421 
patients were randomized. Seven patients were found to be ineligible after 
randomization but before receiving any study drug and five patients or legal 
representatives withheld or withdrew consent after inclusion in the trial; these 
patients were excluded from all analyses. One patient refused ongoing 
participation in the trial after inclusion, including 28-day follow-up, but allowed 
existing data to be included in the analyses. Therefore, 409 patients were 
included at baseline, for safety data and some secondary outcome analyses as 
indicated, and 408 patients were included in the primary “intention-to-treat” 
analysis. In total eight patients in placebo groups were given open-label 
hydrocortisone as “rescue” therapy or for other clinical indications and two 
patients in the norepinephrine groups were given open-label vasopressin (one of 
whom was also one of the eight given open-label hydrocortisone), and these 
patients were included as cross-overs in the “as treated” analysis. The patients 
who did not receive study drug 2 (see figure 1) were allocated to the placebo 
group in the “as treated” analysis.  All cross-overs and patients not receiving the 
second study drug were excluded from the “per protocol” analysis. 
 The treatment groups were well balanced at baseline (Table 1). The study 
drugs were started at a median of 3.5 hours after the diagnosis of shock. In 15% 
of patients study drug 1 was the  first vasopressor administered. For the 309 
(76%) of patients on norepinephrine at randomization, the median dose of open-
label norepinephrine at baseline was 0.16 µg/kg/min. The mean arterial 
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pressure in all treatment groups was similar at baseline and over the first seven 
days (Figure 2a + eFigure 1a) and vasopressin spared the total dose of 
norepinephrine required to maintain the blood pressure (Figure 2b).  
 There was no significant difference in the distribution of kidney failure 
free days between vasopressin and norepinephrine groups, p = 0.88 (Figure 3a). 
The number of survivors who never developed kidney failure was 94/165 
(57.0%) in the vasopressin group and 93/157 (59.2%) in the norepinephrine 
group (absolute difference -2.3, 95%CI -13.0, 8.5%) (Table 2). The median 
number of kidney failure free days in the other patients who died, experienced 
kidney failure, or both at any time was 9 (interquartile range 1–24) in the 
vasopressin group and 13 (interquartile range 1–25) in the norepinephrine 
group (absolute difference -4, 95%CI -11, 5 days). Similar results were obtained 
when using the serum creatinine values and urine output values separately to 
define kidney failure (eTable 2), and the “as treated” and “per protocol” analyses 
gave similar results (eTable 3). 
 Similar quantities of intravenous fluid were given to all groups, and total 
fluid balance, serum lactate levels and heart rate were similar in all groups 
(eTables ,  4, 5, 6 and 7). Serum creatinine levels were lower and urine output 
slightly higher over the first seven days in the vasopressin group compared to 
the norepinephrine group (Figure 3b and 3c, and eTable 8a and 9a) and the rate 
of renal replacement therapy use was 25.4% in the vasopressin group and 35.3% 
in the norepinephrine group (Table 2), odds ratio 0.40, 95%CI 0.20-0.73. There 
was no significant difference in mortality rates between vasopressin and 
norepinephrine groups (28-day mortality, vasopressin group 30.9% versus 
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norepinephrine group 27.5%, absolute difference 3.4%, 95%CI -5.4, 12.3), and 
hydrocortisone and placebo groups (28-day mortality, hydrocortisone group 
30.8% v placebo group 27.5%, absolute difference 3.3%, 95%CI -5.5, 12.1) 
(Table 2 and Figure e4a), and there was no significant  interaction between 
vasopressin and hydrocortisone (p=0.98 from Cox regression model for 28 day 
mortality). There were no differences in rates of other new organ failures or 
organ failure free days between vasopressin and norepinephrine groups (eTable 
10). 
 In the vasopressin group 22 patients had a total of 29 serious adverse 
events and 17 patients in the norepinephrine group had 19 events. The 
breakdown of all serious adverse events by treatment group is given in Table 2. 
In serious adverse events judged by the treating physician as at least “possibly 
related” to the study drugs, the mean dose of vasopressin on the day of the event 
or the day before was 0.06 units/minute and the mean dose of 
norepinephrine/epinephrine was 0.55 µg/kg/minute (0.33 µg/kg/minute in the 
vasopressin group and 0.79 µg/kg/minute in the norepinephrine group). 
 Rates of vasopressin and norepinephrine infusion are shown in eFigures 
1b-d and 2. There was no difference in serum creatinine, urine output, rates of 
kidney failure, use of renal replacement therapy, mortality, or serious adverse 
events between the hydrocortisone group and the placebo group (eTables 8b, 9b, 
11 and eFigures e3 and 4b).  
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Discussion 
 In this multi-center, factorial (2x2), double-blind, randomized clinical trial 
early use of vasopressin to treat septic shock did not increase the number of 
kidney failure free days compared to norepinephrine. Mortality rates were 
similar between all groups and there was no interaction on outcome between 
vasopressin and corticosteroids.   Although these findings do not support the use 
of vasopressin to replace norepinephrine as initial treatment in this situation, 
the confidence interval included a potential clinically important benefit for 
vasopressin, and larger trials may be warranted to assess this further. 
 The rationale for this trial was based on the results of the previous VASST 
study.7 Although there was no significant difference in mortality rates in the 
overall septic shock population in that trial, there was a lower mortality rate in 
the a priori defined subgroup of patients who had less severe shock treated with 
vasopressin compared to norepinephrine (28-day mortality relative risk 0.74 
95% CI, 0.55 to 1.01, p=0.05). There was no difference in mortality in those who 
had more severe shock (defined as norepinephrine ≥15µg/min at baseline). 
Possible explanations for the VASST result might be 1) that vasopressin was 
more effective when used earlier before patients had become too sick (the mean 
time to study drug initiation was approximately 12 hours after meeting 
eligibility), 2) that the patients with more severe shock  might have required a 
higher dose of vasopressin as the maximum rate of vasopressin was limited to 
0.03 units/minute, 3) that there was a harmful interaction between vasopressin 
and high dose norepinephrine, or 4) it could have been a chance finding in a 
subgroup analysis, although the subgroups were large, prospectively defined and 
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randomization was stratified by subgroup. 
 Further analyses from VASST suggested that vasopressin might improve 
kidney function in patients at risk of kidney failure and reduce rates of 
progression to kidney failure and loss, but that it had no effect if acute kidney 
failure was already established at the time of study inclusion.8 This was 
supported by evidence from a study by Lauzier et al5, that demonstrated an 
improvement in creatinine clearance when vasopressin was started in the first 
12 hours of developing vasodilatory shock. Similarly in VASST patients enrolled 
in the first 12 hours tended to have better outcomes with vasopressin treatment 
compared with norepinephrine, but not if enrolled after 12 hours.7 For this 
reason patients in this study were randomized as early as possible, and at a 
maximum of six hours after developing hypotension. Despite this early 
recruitment a number of patients already had developed acute kidney failure at 
the time of inclusion. However, there was no significant difference in the number 
of patients who had kidney failure at any time or progressed to kidney failure 
after randomization. Although there was no significant difference in rates of 
kidney failure, there was a lower rate of use of renal replacement therapy in the 
vasopressin treated patients. The use of renal replacement therapy was not 
controlled in this trial, and it was started based on local clinical decision. It is 
therefore not possible to know why renal replacement therapy was or was not 
started. As the trial was double-blinded it is unlikely to be due to any obvious 
clinician bias. It is possible the difference in rates of renal replacement therapy 
reflects the slightly lower creatinine values and higher urine outputs seen in the 
vasopressin treated patients, particularly on days 3-6. Although use of renal 
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replacement therapy was not the primary outcome of this trial, it is an important 
patient-centered outcome and therefore this result may be important when 
planning patient treatment strategies. 
 To ensure that patients with more severe shock were treated with an 
adequate dose of vasopressin the dose of vasopressin was titrated up to 0.06 
units /minute, double the dose used in VASST. In another randomized clinical 
trial, a dose of 0.067 units /minute restored cardiovascular function more 
effectively than 0.033 units /minute, without a difference in adverse events.9 In 
the previous pilot trial an infusion rate of 0.06 units /minute of vasopressin led 
to mean plasma levels of around 300 pmol/l, well above the physiological levels 
seen in other shock states.11 Although the trial by Lauzier and colleagues5, that 
had demonstrated an improved creatinine clearance, used a vasopressin dose up 
to 0.2 units /minute there was concern that higher doses might lead to adverse 
effects, such as ischemia from excessive vasoconstriction.  The mean dose of 
vasopressin was 0.06 units /min, and the mean dose of 
norepinephrine/epinephrine was 0.55 µg/kg/min, when the potentially drug-
related serious adverse events occurred. In view of the uncertainty about what is 
the ideal blood pressure to target in septic shock,19 clinicians need to balance the 
potential benefits of an increased blood pressure against the risk of vasopressor 
related adverse events, particularly at high dose and should set blood pressure 
targets for individual patients.  
 The other potentially important finding from VASST that informed this 
trial was the potential interaction with corticosteroids.  
There are several possible biological interactions including that vasopressin 
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binds to V1b receptors in the anterior pituitary that then leads to 
adrenocorticotropin hormone release20 and corticosteroids have been shown to 
restore cytokine-mediated down-regulation of vasopressin receptors.21 Patients 
in VASST who received vasopressin and corticosteroids had reduced mortality 
rates compared with patients who received norepinephrine and corticosteroids. 
In contrast to patients who did not receive corticosteroids, patients treated with 
norepinephrine had better outcomes.10 Other retrospective studies also 
suggested that patients treated with the combination of vasopressin and 
corticosteroids had reduced mortality rates compared with patients receiving 
vasopressin alone.22,23 In view of the Surviving Sepsis Guidelines that 
recommend only using hydrocortisone (200mg/day) if hypotension is not 
responding to fluid and vasopressor therapy2, corticosteroids were only 
administered once study drug 1 was at its maximal infusion rate (vasopressin 
0.06 units /minute or norepinephrine 12µg /minute). As in the pilot study11 
corticosteroids reduced vasopressin requirements but there was no difference in 
mortality rates and no evidence of an interaction between vasopressin and 
corticosteroids on outcome. Although not all patients required study drug 2 
(hydrocortisone or placebo) the results were similar in the “as treated” and the 
“per protocol” analyses.  However, since many patients did not require or receive 
study drug 2 the power to assess an interaction was limited and restricts the 
interpretation of this finding. 
 Limitations of this study need to be considered. The multi-center nature 
of the trial was designed to test the effectiveness of early vasopressin use in the 
treatment of septic shock in normal clinical practice. Other co-interventions, 
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timing of initiation of renal replacement therapy or levels of hemodynamic 
monitoring were not controlled, other than specifying that sites should follow 
the international guidelines.14 As the trial was blinded and randomization was 
stratified by center we would expect these other factors to be balanced between 
groups and therefore unlikely to affect the overall result. Another important 
limitation is that only short time outcomes, 28-day and hospital mortality were 
collected, and therefore any long-term differences between treatment groups 
cannot be assessed. Similarly, no formal health economic analysis was originally 
planned but the lower rate of renal replacement therapy in the vasopressin 
treated patients mean that this could be an important future assessment. 
Although there was no difference in the distribution or number of kidney failure 
free days between vasopressin and norepinephrine groups, the 95% confidence 
intervals of the difference between groups has an upper limit of five days in favor 
of vasopressin, which would be clinically important. Therefore, these results are 
still consistent with a potentially clinically important benefit for vasopressin but 
a larger trial would be needed to confirm or refute this. 
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Conclusion: 
 Among adults with septic shock, the early use of vasopressin compared 
with norepinephrine did not improve the number of kidney failure free days.  
Although these findings do not support the use of vasopressin to replace 
norepinephrine as initial treatment in this situation, the confidence interval 
included a potential clinically important benefit for vasopressin, and larger trials 
may be warranted to assess this further. 
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Figure legends: 
 
Figure 1: Recruitment, randomization and patient flow in the VANISH trial 
* Patients could meet more than one exclusion criteria 
 
Figure 2: a) Mean arterial pressure over the first seven days. b) Maximum total 
(study and open-label) norepinephrine dose over the first seven days. Black 
squares represent the median for vasopressin patients, white circles for 
norepinephrine patients. The vertical lines represent the interquartile range. 
Note that day 1 runs from the time of randomization to the end of the “ICU 
calendar day” so is therefore less than 24 hours and varies in duration between 
patients. 
 
Figure 3: Kidney function outcomes a) The number of kidney failure free days 
in each treatment group (the primary outcome) b) Serum creatinine over the 
first seven days. c) Urine output over the first seven days. Black squares 
represent the median for vasopressin group, white circles for norepinephrine 
group. The vertical lines represent the interquartile range.  Day 0 = baseline 
(most recent measurement prior to randomization up to a maximum of 24 
hours). Note that day 1 runs from the time of randomization to the end of the 
“ICU calendar day” so is therefore less than 24 hours and varies in duration 
between patients. 
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Table 1: Baseline characteristics 
 Vasopressin + 
hydrocortisone 
N=101 
Vasopressin + 
placebo 
N=104 
Norepinephrine + 
hydrocortisone 
N=101 
Norepinephrine + 
placebo 
N=103 
Total trial 
population 
N=409 
Age (years) 66 (57, 76) 67 (59, 77) 63 (52, 76) 66 (54, 76) 66 (54, 77) 
Male sex 59 (58) 52 (50) 62 (61) 65 (63) 238 (58) 
Weight (kg) 75 (63, 90) 70 (60, 85) 75 (65, 89) 73 (64, 90) 75 (62, 87) 
Body Mass Index 
(kg/m2) 
26 (23, 32) 24 (22, 29) 26 (23, 30) 25 (23, 30) 26 (22, 30) 
Caucasian ethnicity 85 (84) 89 (86) 87 (86) 88 (85) 349 (85) 
Recent surgical historya 17 (17) 21 (20) 18 (18) 17 (17) 73 (18) 
APACHE II score 24 (19, 30) 24 (19, 29) 24 (20, 30) 23 (18, 30) 24 (19, 30) 
Pre-existing conditions      
 Ischemic Heart Disease 20 (20) 11 (11) 12 (12) 19 (18) 62 (15) 
 Severe COPD 2 (2) 4 (4) 6 (6) 3 (3) 15 (4) 
 Chronic Kidney Failure 9 (9) 8 (8) 5 (5) 5 (5) 27 (7) 
 Cirrhosis 5 (5) 3 (3) 2 (2) 5 (5) 15 (4) 
 Cancer 14 (14) 11 (11) 8 (8) 14 (14) 47 (11) 
 Immunocompromised 9 (9) 4 (4) 8 (8) 7 (7) 28 (7) 
 Diabetes 19 (19) 20 (19) 22 (22) 29 (28) 90 (22) 
Organ failureb      
 Respiratory 32 (32) 39 (38) 40 (40) 38 (38) 149 (37) 
 Kidney 19 (19) 19 (18) 24 (24) 23 (22) 85 (21) 
 Liver 4 (4) 4 (4) 6 (6) 6 (7) 20 (5) 
 Haematological 6 (6) 6 (6) 6 (6) 4 (4) 22 (6) 
 Neurological  33 (35) 33 (33) 32 (34) 30 (31) 128 (33) 
Physiological variables      
 Mean Arterial Pressure 
(mmHg) 
71 (62, 80) 69 (62, 75) 68 (61, 75) 70 (63, 78) 70 (62, 77) 
 Heart Rate (beats/min) 98 (85, 109) 96 (84, 108) 99 (83, 112) 96 (84, 110) 97 (84, 110) 
 Central venous pressure 
(mmHg)c 
12 (9, 17) 13 (10, 16) 13 (9, 17) 13 (8, 17) 13 (9, 17) 
 Lactate (mmol/l) 2.1 (1.4, 4.3) 2.3 (1.5, 3.9) 2.6 (1.4, 4.5) 2.2 (1.4, 3.2) 2.3 (1.4, 4) 
 PaO2/FiO2 (mmHg)  190  (122,318)   189  (122,301)   171 (104,264)   195  (130,328)   188  (121,302)   
 Creatinine (mg/dl)  1.36  (0.89,2.69)   1.26  (0.83,2.02)   1.44  (0.83,2.26)   1.5  (0.84,2.32)   1.38  (0.84,2.32)   
 Bilirubin (mg/dl)  0.94  (0.47,1.62)   0.99  (0.53,1.67)   0.85  (0.51,1.42)   0.79  (0.45,1.45)   0.88  (0.47,1.58)   
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 Platelets (x109/l) 194 (122, 289) 176 (116, 284) 182 (125, 293) 198 (122, 270) 188 (121, 288) 
 GCS  14 (6, 15) 14 (4, 15) 14 (3, 15) 14 (5, 15) 14 (4, 15) 
Mechanical ventilation 55 (54) 58 (56) 62 (61) 61 (59) 236 (58) 
Renal Replacement 
therapy 
2 (2) 4 (4) 2 (2) 3 (3) 11 (3) 
Volume of IV fluid in 
previous 4 hours (mls) 
1200 (757, 2021) 1092 (725, 2010) 1168 (606, 2000) 1100 (613, 2132) 1134 (662, 2039) 
Patients receiving open-
label vasopressor at 
randomisation 
91 (90) 89 (86) 86 (85) 82 (80) 348 (85) 
Time from onset of 
shock to receiving first 
study drug (hrs) 
3.2 (1.8, 5) 3.5 (2, 5.4) 3.7 (1.7, 5) 3.5 (1.4, 5.4) 3.5 (1.8, 5.2) 
Norepinephrine dose at 
randomisation 
(µg/kg/min) 
0.16 (0.1, 0.3) 
(n=76) 
0.15 (0.1, 0.28) 
(n=79) 
0.2 (0.12, 0.42) 
(n=81) 
0.16 (0.1, 0.27) 
(n=73) 
0.16 (0.1, 0.31) 
(n=309) 
Source of infection      
 Lung 43 (44) 39 (38) 44 (45) 39 (38) 165 (41) 
 Abdomen 20 (20) 26 (25) 25 (26) 22 (22) 93 (23) 
 Soft tissue or line 5 (5) 5 (5) 3 (3) 6 (6) 19 (5) 
 Other 30 (31) 32 (31) 26 (27) 35 (34) 123 (31) 
Median (interquartile range) for continuous variables and n (%) for dichotomous and categorical variables. COPD – chronic obstructive pulmonary, APACHE – 
Acute Physiology and Chronic Health Evaluation (range 0-72, a higher score corresponds to more severe illness and a higher risk of death), GCS- Glasgow Coma 
Score (range 3-15, a lower score corresponds to a greater depression of consciousness) 
a Recent surgery is defined as admitted to intensive care unit following surgery bkidney failure is defined as having Acute Kidney Injury stage 3; other organ failures 
defined as having a SOFA score of ≥ 3. c Central venous pressure was only recorded in 234 patients at baseline. See supplemental etable 1 for numbers of other 
missing values at baseline.  
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Table 2. Outcome data in the four treatment groups, and comparing the vasopressin group to norepinephrine group 
 Vasopressin Norepinephrine  
 
Hydrocortisonea Placebo Totala Hydrocortisone Placebo Total 
Vasopressin vs 
Norepinephrine, 
Absolute 
differenceb 
(95% CI) 
28-day survivors who never 
developed kidney failure, 
N/Total (%)c 
46/81 
(56.8) 
48/84 
(57.1) 
94/165 
(57.0) 
46/77 
(59.7) 
47/80 
(58.8) 
93/157 
(59.2) 
-2.3 (-13.0, 8.5)* 
Kidney failure free days in 
other patients, days, median 
(IQR) d 
5 (0-23) 12 (1-25) 9 (1-24) 13 (0-25) 14 (1-24) 13 (1-25) -4 (-11, 5)* 
28-day mortality, N/Total 
(%) 
33/100 
(33.0) 
30/104 
(28.8) 
63/204 
(30.9) 
29/101 
(28.7) 
27/103 
(26.2) 
56/204 
(27.5) 
3.4 (-5.4, 12.3) 
ICU mortality, N/Total (%) 32/100 
(32.0) 
26/104 
(25.0) 
58/204 
(28.4) 
24/101 
(23.8) 
27/103 
(26.2) 
51/204 
(25.0) 
3.4 (-5.2, 12.0) 
Hospital mortality, N/Total 
(%) 
35/100 
(35.0) 
33/104 
(31.7) 
68/204 
(33.3) 
31/101 
(30.7) 
29/103 
(28.2) 
60/204 
(29.4) 
3.9 (-5.1, 12.9) 
Kidney Failure, N/Total (%) 41/101 
(40.6) 
46/104 
(44.2) 
87/205 
(42.4) 
46/101 
(45.5) 
51/103 
(49.5) 
97/204 
(47.5) 
-5.1 (-15.2, 5.0) 
  Survivors 21/67  
(31.3) 
26/74 
(35.1) 
47/141 
(33.3) 
26/72 
(36.1) 
29/76  
(38.2) 
55/148 
(37.2) 
−3.8 (-15.5,7.9) 
  Non-survivors 20/33  
(60.6) 
20/30 
(66.7) 
40/63 
(63.5) 
20/29 
(69) 
22/27 
(81.5) 
42/56 
(75) 
−11.5 (-29.6,6.6) 
Duration of Kidney Failure, 
days, median (IQR) 
4 (1,7) 2 (1,6) 3 (1,7) 3 (2,6) 4 (2,8) 4 (2,8) -1 (2, 0) 
  Survivors 4 (2,7) 3 (2,8) 4 (2,8) 4 (2,8) 4 (3,8) 4 (2,8) 0 (-3, 2) 
  Non-survivors 2 (1,7) 2 (1,3) 2 (1,7) 3 (2,5) 2 (1,8) 3 (2,7) -1 (-3, 0) 
Use of renal replacement 
therapy, N/Total (%) 
29/101 
(28.7) 
23/104 
(22.1) 
52/205 
(25.4) 
32/101 
(31.7) 
40/103 
(38.8) 
72/204 
(35.3) 
-9.9 (-19.3, -0.6) 
  Survivors 15/67 
(22.4) 
13/74 
(17.6) 
28/141 
(19.9) 
15/72 
(20.8) 
18/76 
(23.7) 
33/148 
(22.3) 
−2.4 (-12.5,7.7) 
  Non-survivors 14/33 
(42.4) 
10/30 
(33.3) 
24/63 
(38.1) 
17/29 
(58.6) 
22/27 
(81.5) 
39/56 
(69.6) 
−31.5 (-50.2,-12.9) 
Duration of renal 
replacement therapy, days 
4 (2,7) 3 (2,5) 3 (2,7) 3 (2,8) 4 (2,8) 3 (2,8) 0 (-2, 2) 
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median (IQR) 
  Survivors 4 (2, 8) 3 (3,14) 4 (2,10) 4 (2,10) 6 (2,12) 5 (2,11) -1 (-4, 2) 
  Non-survivors 4 (1,7) 2 (1,4) 2 (1,6) 3 (2,4) 3 (2,6) 3 (2,6) -1 (-2, 2) 
Numbers weaned from 
vasopressors for >24hrs, 
N/Total (%) 
88/101 
(87.1) 
91/104 
(87.5) 
 
179/205 
(87.3) 
91/101 
(90.1) 
88/103 
(85.4) 
179/204 
(87.7) 
0.4 (-6.8, 6.0) 
Time to shock reversal, 
hours, median (IQR) 
50 (28,92) 59 (27,112) 51 (28,99) 46 (23,72) 44 (23,90) 45 (23,75) 6 (-4, 20) 
Use of inotropese, N/Total 
(%) 
31/101 
(30.7) 
24/104 
(23.1) 
55/205 
(26.8) 
24/101 
(23.8) 
17/103 
(16.5) 
41/204 
(20.1) 
6.7 (-1.5, 14.9) 
Duration of mechanical 
ventilation, days median 
(IQR) 
5 (2,10) 6 (3,12) 5 (2,10) 5 (2,16) 5 (2,12) 5 (2,13) 0 (-2, 2) 
Mean total SOFA score, Mean 
± SD 
6.1 (3.4) 5.8 (3.1) 6.0 (3.3) 6.1 (3.1) 6.3 (3.5) 6.2 (3.3) -0.2 (-0.9,0.4) 
ICU length of stay, days 
median (IQR) 
6 (3,10) 7 (3,14) 7 (3,11) 5 (3,15) 6 (3,11) 5 (3,13) 2 (-1, 3) 
Hospital length of stay, days 
median (IQR) 
13 (7,31) 17 (9,40) 16 (7,36) 16 (8,42) 15 (8,36) 16 (8,38) 0 (-5, 4) 
Patients who had one or 
more serious adverse 
events, N/Total (%) 
9/101 
(8.9) 
13/104 
(12.5) 
22/205 
(10.7) 
11/101 
(10.9) 
6/103 
(5.8) 
17/204 
(8.3) 
2.5 (-3.3, 8.2) 
Subcategories of serious 
adverse eventsf 
       
  Digital ischemia, N/Total 
(%) 
4/101 
(4.0) 
7/104 
(6.7) 
11/205 
(5.4) 
2/101 
(2.0) 
1/103 
(1.0) 
3/204 
(1.5) 
3.9 (-0.1, 7.9) 
  Mesenteric ischemia, 
N/Total (%) 
2/101 
(2.0) 
3/104 
(2.9) 
5/205 
(2.4) 
4/101 
(4.0) 
1/103 
(1.0) 
5/204 
(2.5) 
0.0 (-3.0, 3.0) 
  Life threatening 
arrhythmia, N/Total (%) 
2/101 
(2.0) 
0/104 
(0.0) 
2/205 
(0.98) 
1/101 
(1.0) 
4/103 
(3.9) 
5/204 
(2.5) 
-1.5 (-4.5, 1.5) 
  Acute Coronary Syndrome, 
N/Total (%) 
4/101 
(4.0) 
3/104 
(2.9) 
7/205 
(3.4) 
2/101 
(2.0) 
0/103 
(0.0) 
2/204 
(1.0) 
2.5 (-0.9, 5.8) 
  Other, N/Total (%) 2/101 
(2.0) 
2/104 
(1.9) 
4/205 
(2.0) 
3/101 
(3.0) 
1/103 
(1.0) 
4/204 
(2.0) 
0.0 (-2.7, 2.7) 
Median (interquartile range) for continuous variables and n (%) for dichotomous and categorical variables. SOFA – Sequential Organ Failure Assessment (range 0-
20, a higher score corresponds to more severe organ failure)  
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* Primary outcome a One patient in the vasopressin and hydrocortisone group refused ongoing participation in the trial after inclusion, including 28-day follow-up, 
but allowed existing data to be included in the analyses. Their data has been used where possible, therefore the denominator varies between 104/105 or 204/205. b 
Absolute difference in percentage for binary variables and difference in medians for continuous variables.  95% confidence intervals for the difference in medians 
calculated using bootstrapping; figures may not add due to rounding. c 28 day survivors as a proportion of patients with no kidney failure at baseline (one patient 
with no baseline kidney failure data was excluded. d Other patients = those who died and / or had kidney failure at any time. e inotropes defined as dobutamine, 
epinephrine, milrinone, dopamine, dopexamine. f The N of serious adverse events represents the number of patients who had that subcategory of event. Patients 
may have had more than one event. 
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